Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024
25 Aprile 2024 - 10:04PM
Business Wire
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery, and diagnostic solutions to the
pharmaceutical, biotechnology, and life sciences industries,
announced today that it will issue financial results for the first
quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).
Conference call and webcast: The Company will host a
conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9,
2024, to discuss financial results. During the call, management
will refer to a slide presentation which will be available on the
morning of the call on the “Financial Results” page under the
Company's Investor Relations section of its website.
Pre-registration: Participants who pre-register will be
given a conference passcode and unique PIN to gain immediate access
to the call and bypass the live operator. We encourage participants
to pre-register for the conference call using the following link:
STVN conference call pre-registration.
Webcast: A live, listen-only webcast of the call will be
available at the following link: STVN webcast.
Dial in: Those who are unable to pre-register may dial in
by calling:
Italy: +39 02 802 09 11 United Kingdom: +44 1
212 818004 United States: +1 718 705 8796 United States Toll Free:
+1 855 265 6958
Questions during the call: Participants who wish to ask
questions during the call should use the HD webphone link:
https://hditalia.choruscall.com/?$Y2FsbHR5cGU9MiZpbmZvPWNvbXBhbnk=.
Replay: The webcast will be archived for three months on
the Company’s Investor Relations section of its website.
About Stevanato Group Founded in 1949, Stevanato Group is
a leading global provider of drug containment, drug delivery and
diagnostic solutions to the pharmaceutical, biotechnology and life
sciences industries. Stevanato Group delivers an integrated,
end-to-end portfolio of products, processes and services that
address customer needs across the entire drug life cycle at each of
the development, clinical and commercial stages. Stevanato Group’s
core capabilities in scientific research and development, its
commitment to technical innovation and its engineering excellence
are central to its ability to offer value added solutions to
clients. For more information, please visit
www.stevanatogroup.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425570152/en/
Investor Relations Lisa Miles
lisa.miles@stevanatogroup.com Media
media@stevanatogroup.com
Grafico Azioni Stevanato (NYSE:STVN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Stevanato (NYSE:STVN)
Storico
Da Dic 2023 a Dic 2024